Format

Send to

Choose Destination
Curr Opin Immunol. 2015 Jun;34:75-82. doi: 10.1016/j.coi.2015.02.008. Epub 2015 Mar 6.

The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition.

Author information

1
Institute of Biochemistry, Kiel University, Olshausenstrasse 40, Kiel, Germany.
2
Institute of Biochemistry, Kiel University, Olshausenstrasse 40, Kiel, Germany. Electronic address: rosejohn@biochem.uni-kiel.de.

Abstract

Interleukin-6 has long been recognized as a prototypic pro-inflammatory cytokine that is involved in the pathogenesis of all inflammatory diseases. Activation of the gp130 homodimer by IL-6 leads to the initiation of Jak/STAT signaling, a pathway that is often constitutively switched on in inflammatory malignancies. However, a plethora of studies in the last decade has convincingly shown that only signaling via the soluble IL-6R (trans-signaling) accounts for the deleterious effects of IL-6, whereas classic signaling via the membrane-bound receptor is essential for the regenerative and anti-bacterial effects of IL-6 (classic signaling). In this review, we highlight recent developments in the field of IL-6 research, and specifically focus on advances towards a safe and specific inhibition of IL-6 trans-signaling.

PMID:
25749511
DOI:
10.1016/j.coi.2015.02.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center